Figure 2 | Scientific Reports

Figure 2

From: Multi-omics analysis identifies repurposing bortezomib in the treatment of kidney-, nervous system-, and hematological cancers

Figure 2

In vitro analysis confirms that A-375 melanoma, A-172 glioblastoma, and RPMI-8226 multiple myeloma cells are more sensitive to bortezomib than BT-474 and ZR-75–30 breast cancer cells, which is consistent with the GDSC1/GDSC2 dataset. Cell viability analysis depicting the effect of (a) 24h and (b) 72h bortezomib treatment on half-maximal inhibitory concentration (IC50) and area under the curve (AUC) metrics in five cancer cell lines (A-172, A-375, BT-474, RPMI-8226, and ZR-75–30). (c) Representative images showing the effect of different bortezomib concentrations on cell density for the A-375 cell line. (d) Bar chart showing inhibition of the β5 proteasome catalytic activity at different bortezomib concentrations (0–1000 nM) after 2h drug exposure.

Back to article page